CLINICAL_TRIALS
trial_result
· 2022-03-02
Clinical Trial Update: Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome [Phase 1, Phase 2]
Summary
A Cannabidiol expanded access study in medically refractory Sturge-Weber syndrome has completed phase 1 and phase 2, with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Anne Comi, MD | Conditions: Sturge-Weber Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-02